Introduction {#S1}
============

We report a two and a half years old boy from a rural tropical region of Ecuador, who presented with a 6-month history of neck and scalp skin lesions. These papules gradually evolved to become pustular and then xerotic, erythematous-ulcerations (Figures [1](#F1){ref-type="fig"}A,B). Lesional biopsy was consistent with cutaneous histoplasmosis (Figure [1](#F1){ref-type="fig"}C). We initially ruled out secondary immunodeficiencies, including HIV, raising the suspicion of a primary immunodeficiency disease (PIDD).

![**(A,B)** Disseminated vesicular or dry erythematous and ulcerous lesions over the body and scalp of the proband. **(C)** Histological analysis of the dermis showed intense edema, necrosis of the dermal fibers, and pseudo-granulomatous tissue. A few giant cells and a polymorphonuclear infiltrate are observed. Macrophages are present, loaded with oval-shaped parasites, between 2 and 4 µm in size, positive for periodic acid--Schiff staining (intense red-violet), consistent with *Histoplasma capsulatum*. **(D)** Pedigree of the family sequenced in this study. The arrow indicates the proband. The maternal uncles died of unspecified infections before they reached two years of age. The lower panel shows the Sanger sequencing results and familial segregation for the mutation in CD40LG in the affected proband and both unaffected parents. The mutation is inherited from the mother. **(E)** Normal CD4 and CD8 percentages and ratio within the CD3^+^ population. **(F)** Complete absence of CD40L upregulation in patient CD3^+^ population when stimulated for 6 h with SEB as compared to healthy paternal sample.](fped-05-00017-g001){#F1}

During the course of his evaluation, our patient was also identified as having mucous-containing diarrhea positive for *Cryptosporidium parvum*, a pulmonary infection with tracheal aspirates yielding *Pseudomonas aeruginosa* and *Candida albicans*, as well as oral lesions consistent with candidiasis. He additionally had hepatomegaly 3 cm below the costal margin and diffuse lymphadenopathy.

Laboratory studies demonstrated normal white blood cell counts and lymphocyte subpopulations (CD3^+^: 2,410 cells/μL, CD3^+^CD4^+^: 1,501 cells/μL, CD3^+^CD8^+^: 845 cells/μL, and CD19^+^: 682 cells/μL). Serum immunoglobulin levels were as follows: IgG, 251 mg/dL (480--1200 mg/dL); IgA, below detectable limits (33--180 mg/dL); and IgM, 51 mg/dL (54--200 mg/dL).

Amphotericin B, 1 mg/kg/day was provided for 4 weeks, and intravenous immunoglobulin (600 mg/kg) was administered. After a 2-month hospitalization, the patient was discharged with a prophylactic therapy regimen consisting of trimethoprim/sulfamethoxazole (80/400 mg) every 3 days, itraconazole (100 mg) daily for 2 months and then every 3 days for an additional year, and IVIG 400 mg/kg every 6 weeks. For the past 2 years, the patient has been free of infection with an approximate IgG trough level between 409 and 560 mg/dL.

The patient is the only son of unrelated and healthy parents. Family history was notable for two maternal uncles who died in childhood from pneumonia and diarrhea---suggesting an X-linked recessive trait for susceptibility to severe infections.

The patient's infections, altered laboratory values and both personal and familial history, suggested a PIDD, probably an X-linked combined immunodeficiency. Given the lack of tools to further investigate the immunology of our patient at our center in Ecuador, as well as the relatively broad differential diagnosis surrounding combined immunodeficiency and *Histoplasma* susceptibility, we performed whole exome sequencing (WES) as a family trio (patient, mother, and father) as part of an ongoing collaboration with the Baylor-Hopkins Center for Mendelian Genomics ([@B1]). Exome capture was performed with the in-house developed BCM-HGSC Core design (52 Mb; Roche NimbleGen, Madison, WI, USA), as previously described ([@B2]). The variant calling was performed by the ATLAS2 suite ([@B3]), identifying a consecutive dinucleotide substitution at the exon 2 of the *CD40LG* in the proband (Table [1](#T1){ref-type="table"}), as the most probable variant associated with our patient's phenotype. This mutation creates a premature stop codon (NM_000074:exon2:c.233_234delinsAA:p.S78\*), predicted to result in the loss of the entire extracellular portion of the protein (including the TNF-like domain required for the interaction with CD40) or a complete loss-of-function allele due to mRNA instability and nonsense-mediated decay as predicted by our algorithm. This variant was not reported at ExAC database at the time of the publication and was confirmed by Sanger sequencing in the family trio (Figure [1](#F1){ref-type="fig"}D). The mother was a healthy carrier, and the variant thus segregated with the family history. Other gene variant information from the WES data of the affected individual is listed in Table [1](#T1){ref-type="table"}. While this variant would represent a novel mutation, it suggests the diagnosis of hyper-IgM (HIGM) syndrome, and it is consistent with several reported nonsense or frameshift mutations in early codons associated with *CD40LG* deficiency ([@B4]). Induced expression of CD40L after staphylococcal enterotoxin B superantigen stimulation was examined, and complete lack of expression of the protein by the CD4^+^ T cells of the patient was observed (Figures [1](#F1){ref-type="fig"}E,F).

###### 

**Variant information**. The dinucleotide substitution is predicted by conceptual translation to result in a PTC at position 78. The bioinformatics prediction suggests a likely disease causing mutation associated with HIGM1.

  Gene name                         *CD40LG*                                                *CD40LG*
  --------------------------------- ------------------------------------------------------- -----------
  Chromosome                        chrX                                                    chrX
  Position (hg19)                   135732501                                               135732502
  Sequence: reference/alternative   C/A                                                     C/A
  Proband: reference/alternative    4/160                                                   4/168
  Mother: reference/alternative     163/126                                                 162/125
  Father: reference/alternative     147/0                                                   143/0
  Mutation type                     Indel                                                   
  Refseq                            NM_000074                                               
  Mutation: cDNA                    c.233_234delinsAA                                       
  Mutation: protein                 p.Ser78\*                                               
  Predicted effect                  Premature truncating codon (PTC), disease causing       
  Associated phenotype/MIM number   Immunodeficiency with hyper-IgM, type 1; HIGM1/308230   

Background and Discussion {#S2}
=========================

Hyper-IgM is a well-known PIDD caused by defects in class-switch recombination and/or B cell costimulation. It commonly presents with *Pneumocystis jirovecii* pneumonia and *Cryptosporidium parvum* diarrhea or more standard consequences of hypogammaglobulinemia ([@B4]). Our patient presented with diarrhea and pneumonia, and we confirmed the presence of *Cryptosporidium parvum* in the feces. Susceptibility to the microorganism isolated from the tracheal aspirate, *P. aeruginosa* and *Candida albicans*, while not common in HIGM, has been previously reported ([@B5], [@B6]). Interestingly, our patient presented with a low serum IgM level, and although the disease name suggests high levels of IgM, in at least 50% of cases of *CD40LG* deficiency, the IgM level can be normal or even low ([@B7]).

The main presentation in our patient was the histoplasmosis, although uncommon in HIGM, it has been previously reported. Interestingly, these cases have been reported in areas considered endemic for histoplasmosis ([@B8]): the American cases near to the Mississippi River Valley ([@B9], [@B10]) and the Latin-American in Brazil and Argentina ([@B5], [@B11]). Additional factors such as bird contact, presence of guano soil, or farming activities inside the endemic areas seem to be important ([@B8]). Remarkably, our patient family lives in an isolated rural region in the north of Ecuador with exclusive dedication to farming. Since *Histoplasma* infections even inside endemic areas are commonly observed in patients with risk factors like HIV or old males after years of smoking ([@B8]); in children without risk factors and severe histoplasmosis, who live in endemic areas, HIGM may represent a more likely presentation for this diagnosis. Also while lymphadenopathy in HIGM is rare, our patient was likely to have this as a manifestation of the histoplasmosis. Unfortunately, it was not possible to biopsy the lymph nodes or the liver and thus we were not able to confirm this. Nevertheless, it has been previously reported that in endemic areas, children with histoplasmosis could develop the infection in the peripheral lymph nodes ([@B12]), suggesting again that environmental influences are essential, and thus the need to think about PIDD from a geographical region-specific perspective.

Concluding Remarks {#S3}
==================

We present detailed clinical findings in a patient with X-linked HIGM due to a novel *indel* mutation in *CD40LG*, for whom the diagnosis was confirmed after WES was performed. The unusual infections in our case suggest that in children with severe histoplasmosis, resident in endemic areas, HIGM should be considered as a diagnosis.
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